Literature DB >> 25129436

Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Irina Tretyakova1, Brian Nickols1, Rachmat Hidajat1, Jenny Jokinen2, Igor S Lukashevich2, Peter Pushko3.   

Abstract

Yellow fever (YF) causes an acute hemorrhagic fever disease in tropical Africa and Latin America. To develop a novel experimental YF vaccine, we applied iDNA infectious clone technology. The iDNA represents plasmid that encodes the full-length RNA genome of 17D vaccine downstream from a cytomegalovirus (CMV) promoter. The vaccine was designed to transcribe the full-length viral RNA and to launch 17D vaccine virus in vitro and in vivo. Transfection with 10 ng of iDNA plasmid was sufficient to start replication of vaccine virus in vitro. Safety of the parental 17D and iDNA-derived 17D viruses was confirmed in AG129 mice deficient in receptors for IFN-α/β/γ. Finally, direct vaccination of BALB/c mice with a single 20 μg dose of iDNA plasmid resulted in seroconversion and elicitation of virus-specific neutralizing antibodies in animals. We conclude that iDNA immunization approach combines characteristics of DNA and attenuated vaccines and represents a promising vaccination strategy for YF.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  17D vaccine; DNA vaccine; Flavivirus; Live attenuated vaccine; YFV; Yellow fever virus

Mesh:

Substances:

Year:  2014        PMID: 25129436      PMCID: PMC4252618          DOI: 10.1016/j.virol.2014.07.050

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

Authors:  J Lang; J Zuckerman; P Clarke; P Barrett; C Kirkpatrick; C Blondeau
Journal:  Am J Trop Med Hyg       Date:  1999-06       Impact factor: 2.345

2.  High fidelity of yellow fever virus RNA polymerase.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Simeon W Ocran; Fred Mitchell; Megan Parsons; Caroline Penal; Soheila Girakhoo; Svetlana O Pougatcheva; Juan Arroyo; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

Authors:  V Barban; Y Girerd; M Aguirre; S Gulia; F Pétiard; P Riou; B Barrere; J Lang
Journal:  Vaccine       Date:  2006-08-01       Impact factor: 3.641

4.  Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.

Authors:  J J Schlesinger; M W Brandriss; C B Cropp; T P Monath
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

5.  Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.

Authors:  R B Tesh; H Guzman; A P da Rosa; P F Vasconcelos; L B Dias; J E Bunnell; H Zhang; S Y Xiao
Journal:  J Infect Dis       Date:  2001-04-17       Impact factor: 5.226

Review 6.  From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Bruno Guy; Beatrice Barrere; Claire Malinowski; Melanie Saville; Remy Teyssou; Jean Lang
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

Review 7.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

8.  E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

9.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

Review 10.  Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa.

Authors:  Andrew Beck; Hilda Guzman; Li Li; Brett Ellis; Robert B Tesh; Alan D T Barrett
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14
View more
  11 in total

Review 1.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

2.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

3.  Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice.

Authors:  Brian Nickols; Irina Tretyakova; Alexander Tibbens; Elena Klyushnenkova; Peter Pushko
Journal:  Virology       Date:  2017-09-19       Impact factor: 3.616

Review 4.  The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Authors:  Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy
Journal:  Expert Rev Vaccines       Date:  2019-02-11       Impact factor: 5.217

Review 5.  Historical Perspectives on Flavivirus Research.

Authors:  Michael R Holbrook
Journal:  Viruses       Date:  2017-04-30       Impact factor: 5.048

6.  Single-Round Infectious Particle Production by DNA-Launched Infectious Clones of Bungowannah Pestivirus.

Authors:  Anja Dalmann; Kerstin Wernike; Eric J Snijder; Nadia Oreshkova; Ilona Reimann; Martin Beer
Journal:  Viruses       Date:  2020-08-04       Impact factor: 5.048

7.  Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.

Authors:  Sapna Sharma; Michael A Schmid; Lorena Sanchez Felipe; Jana Grenelle; Suzanne J F Kaptein; Lotte Coelmont; Johan Neyts; Kai Dallmeier
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

8.  A single-dose live attenuated chimeric vaccine candidate against Zika virus.

Authors:  Wei-Xin Chin; Regina Ching Hua Lee; Parveen Kaur; Tian Sheng Lew; Thinesshwary Yogarajah; Hao Yuin Kong; Zi-Yun Teo; Cyrill Kafi Salim; Rong-Rong Zhang; Xiao-Feng Li; Sylvie Alonso; Cheng-Feng Qin; Justin Jang Hann Chu
Journal:  NPJ Vaccines       Date:  2021-01-29       Impact factor: 7.344

9.  Infectious RNA vaccine protects mice against chikungunya virus infection.

Authors:  Inga Szurgot; Karl Ljungberg; Beate M Kümmerer; Peter Liljeström
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

10.  Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool.

Authors:  Chee Wah Tan; Han Kang Tee; Michelle Hui Pheng Lee; I-Ching Sam; Yoke Fun Chan
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.